Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E207.58 EPS (ttm)0.78 Insider Own0.20% Shs Outstand251.65M Perf Week2.52%
Market Cap40.74B Forward P/E53.90 EPS next Y3.00 Insider Trans-56.15% Shs Float251.65M Perf Month11.55%
Income195.50M PEG3.03 EPS next Q0.53 Inst Own95.10% Short Float1.79% Perf Quarter4.73%
Sales2.30B P/S17.75 EPS this Y80.10% Inst Trans-2.68% Short Ratio2.89 Perf Half Y-0.77%
Book/sh7.16 P/B22.61 EPS next Y58.94% ROA13.30% Target Price183.46 Perf Year98.98%
Cash/sh7.20 P/C22.48 EPS next 5Y68.61% ROE26.80% 52W Range80.06 - 167.85 Perf YTD8.04%
Dividend- P/FCF49.99 EPS past 5Y-39.40% ROI-0.30% 52W High-2.00% Beta1.58
Dividend %- Quick Ratio3.10 Sales past 5Y3.80% Gross Margin89.20% 52W Low105.46% ATR3.42
Employees2150 Current Ratio3.30 Sales Q/Q39.70% Oper. Margin11.70% RSI (14)74.65 Volatility2.29% 2.19%
OptionableYes Debt/Eq0.33 EPS Q/Q-159.40% Profit Margin17.90% Rel Volume2.66 Prev Close161.91
ShortableYes LT Debt/Eq0.32 EarningsJan 31 AMC Payout0.00% Avg Volume1.56M Price164.49
Recom1.80 SMA206.40% SMA5010.66% SMA20016.45% Volume925,795 Change1.59%
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Mar-31-17Upgrade Maxim Group Hold → Buy $143
Mar-17-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-09-17Initiated UBS Buy $106
Mar-01-17Initiated Citigroup Buy $105
Jan-26-17Reiterated Stifel Buy $108 → $100
Dec-15-16Initiated Oppenheimer Perform
Oct-24-16Downgrade H.C. Wainwright Buy → Neutral $85
Sep-15-16Reiterated Stifel Buy $105 → $109
Jan-19-18 04:39PM  Which Biotech Stocks Could Surprise To The Upside On Earnings? Investor's Business Daily
10:36AM  Weekly CFO Sells Highlight GuruFocus.com
Jan-18-18 01:55PM  3 Biotech Stocks Start Healthy in 18: Will the Rally Last? InvestorPlace
12:45PM  Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label Zacks
09:25AM  3 Top-Ranked Drug Stocks That Are Broker Favorites InvestorPlace
07:02AM  3 Top-Ranked Drug Stocks that are Broker Favorites Zacks
Jan-17-18 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $15.6 million of Shares GuruFocus.com
09:01AM  Vertex Pharmaceuticals to Target 90% of Cystic Fibrosis Patients Market Realist
08:23AM  BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day Zacks
07:31AM  Vertex Pharmaceuticals Has Robust Late-Stage Research Pipeline Market Realist
Jan-16-18 03:11PM  3 Biotech Stocks Start Healthy in '18: Will the Rally Last? Zacks
10:45AM  Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? Market Realist
09:15AM  Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance Market Realist
07:40AM  Analyst Recommendations for Vertex Pharmaceuticals in January Market Realist
Jan-12-18 03:18PM  Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today Motley Fool
09:16AM  The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex Zacks
Jan-11-18 09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
Jan-10-18 05:40PM  A Look at Ioniss 3Q17 Revenue Stream Market Realist
05:20PM  How Did Bioverativ Perform in 3Q17? Market Realist
03:49PM  Analysts Recommendations for Bioverativ in January 2018 Market Realist
04:00AM  Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation Business Wire
Jan-09-18 04:43PM  What Should We Expect From Vertex Pharmaceuticals Incorporateds (NASDAQ:VRTX) Earnings Over The Next Few Years? Simply Wall St.
10:23AM  Hows Incytes Valuation in January 2018? Market Realist
06:09AM  10 Things to Expect From Vertex Pharmaceuticals in 2018 Motley Fool
Jan-08-18 03:42PM  Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma Zacks
11:55AM  Vertex Pharma's Earnings Preview Benzinga
Jan-06-18 10:34AM  3 Big Biotech Stocks to Buy in January Motley Fool
Jan-05-18 01:48PM  Why CRISPR Therapeutics AG Stock Is Rising Today Motley Fool
Jan-04-18 07:13PM  The 3 Best-Performing Healthcare Stocks in the S&P 500 in 2017 Motley Fool
07:01PM  Cramer: 2017 Was a Year of Resurrection and Revival TheStreet.com
10:47AM  Here's What Pushed Crispr Therapeutics AG Up 23.6% in December Motley Fool
Jan-03-18 04:01PM  Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results Business Wire
07:11AM  Will These 2 Large-Cap Biotechs Be on Investor Radar in '18? Zacks
Jan-02-18 04:11PM  Why These 2 Biotechs Could Outperform Amid 'Hyper-Competition' Investor's Business Daily
01:10PM  Analyst names Vertex and Alexion 'top picks for 2018' American City Business Journals
08:13AM  These 4 S&P 500 Stocks Doubled in 2017 Motley Fool
Dec-29-17 01:16PM  A Market Cynic's Biotech Year In Review Forbes
Dec-27-17 05:37PM  Stocks trading at a discount according to Wall Street's a... CNBC Videos
Dec-26-17 01:16PM  Vertex Pharmaceuticals, Inc. Value Analysis (NASDAQ:VRTX) : December 26, 2017 Capital Cube
09:15AM  Is It Time To Sell Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Based Off Its PE Ratio? Simply Wall St.
Dec-22-17 11:45AM  Q&A: Vertex Chief Talks About Company's 'Transformational Year' Investor's Business Daily
10:52AM  10 Top S&P 500 Stocks in 2017 InvestorPlace
07:19AM  Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US : December 22, 2017 Capital Cube
Dec-21-17 06:04AM  3 Great Stocks for Your IRA Motley Fool
Dec-19-17 06:00AM  Biotech Stocks Set to Rebound 7% by January Investopedia
Dec-14-17 08:10AM  Todays Research Reports on Stocks to Watch: Teva Pharmaceutical and Vertex Pharmaceuticals ACCESSWIRE
Dec-13-17 07:38AM  Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs Zacks
07:24AM  What Investors Should Know About Vertex Pharmaceuticals Incorporateds (undefined:VRTX) Financial Strength Simply Wall St.
07:07AM  Vertex Pharmaceuticals Could Be Bought Out for $205 in 2018: Deutsche Bank TheStreet.com
Dec-12-17 08:30AM  Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and -Thalassemia Business Wire
Dec-11-17 08:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $17.7 million of Shares GuruFocus.com
09:02AM  Analyst Recommendations for Alexion in December 2017 Market Realist
08:20AM  4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018 Zacks
07:32AM  The 5 Best Stocks in the S&P 500 in 2017 Motley Fool
Dec-10-17 09:41AM  3 Growth Stocks I'd Buy Right Now Motley Fool
Dec-08-17 11:51AM  Vertex Kalydeco Study Successful in Children Aged 1-2 Years Zacks
09:57AM  Why Biotech Stocks May Wait A While Before Feeling The Love Investor's Business Daily
Dec-07-17 08:00AM  Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years Business Wire
06:30AM  The Best Investing Advice for 2018 From Fortunes Experts Fortune
Dec-06-17 06:00AM  5 Stocks With More Room to Run Morningstar
Dec-04-17 01:45PM  Analysts Recommendations for Regeneron Market Realist
08:06AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Dec-03-17 09:09AM  5 Top Biotech Stocks to Buy Now Motley Fool
Dec-01-17 08:07AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Nov-28-17 06:31AM  The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex Zacks
Nov-26-17 09:03AM  3 Stocks That Could Put Amazon's Returns to Shame Motley Fool
Nov-21-17 08:22AM  3 Stocks That Have Doubled and Still Have Room to Grow Motley Fool
Nov-20-17 05:34PM  Galapagos Pops To Vertex's Detriment But Can It Compete? Investor's Business Daily
09:44AM  Galapagos' CF Candidate Shows Potential in Phase II Study Zacks
Nov-17-17 07:09AM  Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3 Zacks
Nov-15-17 08:07AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
08:00AM  Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global Discovering Underlying Factors of Influence GlobeNewswire
Nov-14-17 08:06AM  See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc. Markit
Nov-13-17 02:20PM  Vertex Gets CHMP Recommendation for Orkambi Label Expansion Zacks
01:30PM  ETFs with exposure to Vertex Pharmaceuticals, Inc. : November 13, 2017 Capital Cube
07:30AM  Earnings Review and Free Research Report: Vertexs Revenue Soared 40%; Adjusted EPS Rocketed 212% ACCESSWIRE
07:00AM  Vertex Is a Rare-Disease Powerhouse Morningstar
Nov-10-17 07:30AM  Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union Business Wire
Nov-06-17 03:08PM  Edited Transcript of VRTX earnings conference call or presentation 25-Oct-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-03-17 05:06PM  Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug' Investor's Business Daily
11:00AM  Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF Business Wire
10:53AM  These 3 Stocks Look Expensive but Are Actually Cheap Motley Fool
10:34AM  Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine Business Wire
Nov-02-17 08:32PM  Why Vertex Pharmaceuticals Incorporated (VRTX) Delivered An Inferior ROE Compared To The Industry Simply Wall St.
04:01PM  Vertex to Present at the Credit Suisse Healthcare Conference on November 7 Business Wire
12:42PM  ETFs with exposure to Vertex Pharmaceuticals, Inc. : November 2, 2017 Capital Cube
Nov-01-17 09:32AM  Vertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Capital Cube
08:30AM  Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers Business Wire
Oct-27-17 07:15PM  Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline Motley Fool
05:50PM  Analyst Recommendations for Vertex Pharmaceuticals in October Market Realist
04:17PM  Vertex Pharmaceuticals Performance in 3Q17 Market Realist
02:23PM  Biotech stocks are getting slammed by earnings and Trump's Tweets: NYSE trader Yahoo Finance Video
07:40AM  Corporate News Blog - Capricor to Present 12-Month Results From HOPE-1 Trial in Duchenne Muscular Dystrophy at AHA Scientific Sessions 2017 ACCESSWIRE
Oct-26-17 11:51AM  Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View Zacks
09:58AM  Biotech Gets Crushed byCelgene? Barrons.com
Oct-25-17 05:28PM  Three Biotech Firms Top Third-Quarter Views But Only One Pops Investor's Business Daily
05:03PM  First Look at Vertex Pharmaceuticals Incorporated (VRTX) 3Q:17 Results SmarterAnalyst
04:49PM  Vertex posts wider net loss, raises cystic fibrosis sales outlook Reuters
04:17PM  Vertex reports 3Q loss Associated Press
04:01PM  Vertex Reports Third-Quarter 2017 Financial Results Business Wire
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; CRISPR Therapeutics AG; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 16Option Exercise96.872,125205,84944,077Jan 17 04:34 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 16Option Exercise96.871,719166,52056,143Jan 17 04:38 PM
LEIDEN JEFFREY MCEO & PresidentJan 16Option Exercise46.7299,5634,651,914232,060Jan 17 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 16Sale158.282,125336,34541,952Jan 17 04:34 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 16Sale157.281,719270,35854,424Jan 17 04:38 PM
SMITH IAN FEVP, COOJan 16Sale157.292,125334,23240,888Jan 17 04:40 PM
LEIDEN JEFFREY MCEO & PresidentJan 16Sale156.9999,56315,630,614132,497Jan 17 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 16Sale156.9956,2508,830,75549,761Jan 17 04:46 PM
Parini MichaelEVP, CL&AOJan 12Option Exercise90.292,125191,86631,068Jan 16 05:01 PM
Parini MichaelEVP, CL&AOJan 12Sale157.162,125333,96528,943Jan 16 05:01 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 11Option Exercise109.144,250463,84546,202Jan 12 04:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 11Sale159.004,250675,75041,952Jan 12 04:16 PM
Bhatia Sangeeta N.DirectorJan 05Option Exercise126.6810,7531,362,19014,706Jan 09 05:33 PM
Bhatia Sangeeta N.DirectorJan 05Sale156.0010,7531,677,4683,953Jan 09 05:33 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 02Option Exercise73.513,438252,72757,862Jan 03 04:56 PM
Graney ThomasChief Financial OfficerJan 02Sale149.95777116,5118,789Jan 03 04:49 PM
Chodakewitz JeffreyEVP GMDA, CMOJan 02Sale151.803,438521,89554,424Jan 03 04:56 PM
Silva Paul MSVP & Corp ControllerDec 27Option Exercise77.311,28999,65317,923Dec 28 04:31 PM
Silva Paul MSVP & Corp ControllerDec 27Sale152.311,289196,32816,634Dec 28 04:31 PM
LEIDEN JEFFREY MCEO & PresidentDec 11Sale141.35125,00017,668,896132,497Dec 11 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale149.1230645,630106,011Nov 17 04:48 PM
Silva Paul MSVP & Corp ControllerNov 15Sale147.29233,38816,634Nov 17 04:46 PM
SMITH IAN FEVP, COONov 15Sale147.2971,03140,888Nov 17 04:44 PM
Sachdev AmitEVP, CRONov 15Sale147.298312,22550,710Nov 17 04:41 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale147.2922132,55141,952Nov 17 04:37 PM
SMITH IAN FEVP, COONov 06Option Exercise77.314,250328,56845,138Nov 07 05:26 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 06Option Exercise77.314,250328,56846,202Nov 07 05:15 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 06Sale148.174,250629,72341,952Nov 07 05:15 PM
SMITH IAN FEVP, COONov 06Sale150.004,250637,50040,888Nov 07 05:26 PM
Chodakewitz JeffreyEVP GMDA, CMONov 03Option Exercise109.143,594392,24958,018Nov 06 05:50 PM
Parini MichaelEVP, CL&AONov 03Option Exercise86.522,330201,59231,139Nov 07 05:23 PM
Bhatia Sangeeta N.DirectorNov 03Option Exercise93.517,073661,39611,026Nov 07 05:12 PM
SMITH IAN FEVP, COONov 03Option Exercise91.052,155196,21343,043Nov 07 05:26 PM
SMITH IAN FEVP, COONov 03Sale150.002,155323,25040,888Nov 07 05:26 PM
Parini MichaelEVP, CL&AONov 03Sale149.502,330348,33528,809Nov 07 05:23 PM
Bhatia Sangeeta N.DirectorNov 03Sale143.057,0731,011,7933,953Nov 07 05:12 PM
Chodakewitz JeffreyEVP GMDA, CMONov 03Sale144.693,594520,01654,424Nov 06 05:50 PM
Chodakewitz JeffreyEVP GMDA, CMONov 02Option Exercise91.051,796163,52656,220Nov 06 05:50 PM
Chodakewitz JeffreyEVP GMDA, CMONov 02Sale144.761,796259,98254,424Nov 06 05:50 PM
Sachdev AmitEVP, CROOct 31Sale145.0540,0005,802,08450,710Oct 31 06:12 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 31Sale145.0560,0008,703,16154,424Oct 31 06:15 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerOct 31Sale144.8175,00010,860,64541,952Oct 31 06:16 PM
SMITH IAN FEVP, COOOct 31Sale145.0675,00010,879,85840,888Oct 31 06:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerOct 27Option Exercise96.872,125205,849119,077Oct 31 06:16 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerOct 27Sale143.976,290905,598116,952Oct 31 06:16 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 16Option Exercise96.871,718166,423116,142Oct 18 05:35 PM
SMITH IAN FEVP, COOOct 16Option Exercise96.872,125205,849118,013Oct 18 05:41 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 16Sale155.191,718266,610114,424Oct 18 05:35 PM
SMITH IAN FEVP, COOOct 16Sale155.612,125330,671115,888Oct 18 05:41 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86630,934Oct 16 04:59 PM
Parini MichaelEVP, CL&AOOct 12Sale152.932,125324,97628,809Oct 16 04:59 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 02Option Exercise73.513,437252,654117,861Oct 04 05:01 PM
Chodakewitz JeffreyEVP GMDA, CMOOct 02Sale151.643,437521,198114,424Oct 04 05:01 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 31Option Exercise91.051,796163,526107,807Sep 05 04:42 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 31Sale160.001,796287,360106,011Sep 05 04:42 PM
SMITH IAN FEVP, CFO & COOAug 07Option Exercise77.314,250328,568120,138Aug 09 04:33 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 07Option Exercise77.314,250328,568125,367Aug 09 04:36 PM
Silva Paul MSVP & Corp ControllerAug 07Option Exercise77.311,28999,65317,923Aug 09 04:38 PM
SMITH IAN FEVP, CFO & COOAug 07Sale155.394,250660,415115,888Aug 09 04:33 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 07Sale152.884,250649,740121,117Aug 09 04:36 PM
Silva Paul MSVP & Corp ControllerAug 07Sale152.881,289197,06216,634Aug 09 04:38 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 03Option Exercise109.143,594392,249118,018Aug 04 04:42 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59231,139Aug 04 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise109.144,250463,845125,367Aug 04 04:53 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 03Sale154.193,594554,149114,424Aug 04 04:42 PM
Parini MichaelEVP, CL&AOAug 03Sale155.722,330362,82828,809Aug 04 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale155.724,250661,810121,117Aug 04 04:53 PM
SMITH IAN FEVP, CFO & COOAug 02Option Exercise91.052,155196,213118,043Aug 04 04:48 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,923Aug 04 04:36 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 02Option Exercise91.051,796163,526116,220Aug 04 04:42 PM
Chodakewitz JeffreyEVP GMDA, CMOAug 02Sale154.131,796276,811114,424Aug 04 04:42 PM
Silva Paul MSVP & Corp ControllerAug 02Sale151.801,289195,67016,634Aug 04 04:36 PM
SMITH IAN FEVP, CFO & COOAug 02Sale154.172,155332,236115,888Aug 04 04:48 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 31Option Exercise83.362,125177,140123,242Aug 02 04:44 PM
Silva Paul MSVP & Corp ControllerJul 31Option Exercise83.3686071,69017,494Aug 02 04:47 PM
SMITH IAN FEVP, CFO & COOJul 31Option Exercise83.362,125177,140118,013Aug 02 04:51 PM
LEIDEN JEFFREY MCEO & PresidentJul 31Option Exercise45.1111,063499,052268,455Aug 02 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 31Sale152.992,125325,104121,117Aug 02 04:44 PM
Silva Paul MSVP & Corp ControllerJul 31Sale152.99860131,57116,634Aug 02 04:47 PM
SMITH IAN FEVP, CFO & COOJul 31Sale152.882,125324,865115,888Aug 02 04:51 PM
LEIDEN JEFFREY MCEO & PresidentJul 31Sale152.8111,0631,690,552257,392Aug 02 04:56 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 21Option Exercise131.892,125280,266133,592Jul 21 07:58 PM
Silva Paul MSVP & Corp ControllerJul 21Sale161.913,437556,49016,634Jul 21 08:10 PM
SMITH IAN FEVP, CFO & COOJul 21Sale160.7210,3501,663,413115,888Jul 21 08:09 PM
Sachdev AmitEVP, CROJul 21Sale160.788,6251,386,69190,710Jul 21 08:07 PM
LEIDEN JEFFREY MCEO & PresidentJul 21Sale160.7432,2505,184,008257,392Jul 21 08:04 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 21Sale160.736,9001,109,022114,424Jul 21 08:02 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 21Sale161.2212,4752,011,271121,117Jul 21 07:58 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 19Option Exercise107.2589,4009,587,718220,867Jul 21 07:58 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 19Option Exercise84.4928,9792,448,338134,990Jul 21 08:00 PM
Chodakewitz JeffreyEVP GMDA, CMOJul 19Option Exercise107.1438,6464,140,487161,157Jul 21 08:02 PM
Parini MichaelEVP, CL&AOJul 19Option Exercise89.4810,829968,97039,638Jul 21 08:05 PM
LEIDEN JEFFREY MCEO & PresidentJul 19Option Exercise46.56184,3748,584,824474,016Jul 21 08:04 PM
Sachdev AmitEVP, CROJul 19Option Exercise77.3120,0001,546,200119,335Jul 21 08:07 PM
Silva Paul MSVP & Corp ControllerJul 19Option Exercise75.9140,0063,036,87060,077Jul 21 08:10 PM
SMITH IAN FEVP, CFO & COOJul 19Option Exercise84.11123,40010,379,726249,638Jul 21 08:09 PM
SMITH IAN FEVP, CFO & COOJul 19Sale161.00123,40019,867,400126,238Jul 21 08:09 PM
Sachdev AmitEVP, CROJul 19Sale161.0020,0003,220,00099,335Jul 21 08:07 PM
Parini MichaelEVP, CL&AOJul 19Sale161.0010,8291,743,46928,809Jul 21 08:05 PM
Silva Paul MSVP & Corp ControllerJul 19Sale161.0040,0066,440,96620,071Jul 21 08:10 PM